Urologix, Inc. (ULGX)

OTCMKTS · Delayed Price · Currency is USD

0.0001

-0.0001 (-50.00%)

At close: Mar 4, 2026

9,900% (1Y)

Market Cap	2.13K
Revenue (ttm)	12.00M
Net Income (ttm)	-4.67M
Shares Out	21.28M
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	16,847
Open	0.0001
Previous Close	0.0002
Day's Range	0.0001 - 0.0001
52-Week Range	0.0000 - 0.0251
Beta	-126.31
RSI	48.17
Earnings Date	n/a

About Urologix

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethr... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 1991

Employees 61

Stock Exchange OTCMKTS

Ticker Symbol ULGX

Full Company Profile

Financial Performance

In fiscal year 2014, Urologix's revenue was $14.01 million, a decrease of -15.00% compared to the previous year's $16.48 million. Losses were -$7.61 million, 77.3% more than in 2013.

Financial Statements

News

There is no news available yet.